These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23417736)

  • 21. Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis.
    Hough D; Nuamah IF; Lim P; Sampson A; Gagnon DD; Rothman M
    J Clin Psychopharmacol; 2009 Oct; 29(5):496-7. PubMed ID: 19745652
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
    Amatniek J; Canuso CM; Deutsch SI; Henderson DC; Mao L; Mikesell C; Rodriguez S; Sheehan J; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Apr; 8(1):8-20. PubMed ID: 23428785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose pattern and effectiveness of paliperidone extended-release tablets in patients with schizophrenia.
    Lee JS; Ahn JH; Lee JI; Kim JH; Jung I; Lee CU; Lee JY; Lee SI; Kim CY
    Clin Neuropharmacol; 2011; 34(5):186-90. PubMed ID: 21725234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial.
    Fernández-Mayoralas DM; Fernández-Jaén A; Muñoz-Jareño N; Calleja-Pérez B; Fernández-Perrone AL; Arribas SL
    Clin Neuropharmacol; 2012; 35(5):227-30. PubMed ID: 22935606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paliperidone: a new extended-release oral atypical antipsychotic.
    Dlugosz H; Nasrallah HA
    Expert Opin Pharmacother; 2007 Oct; 8(14):2307-13. PubMed ID: 17927485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach.
    Mauri M; Mauri MC; Adami M; Reggiardo G; Giulio C
    Int Clin Psychopharmacol; 2015 Nov; 30(6):329-37. PubMed ID: 26230269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
    Janicak PG; Wu JH; Mao L
    Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D
    J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].
    Wang Y; Li WS; Gu DK; Yang N; Lu Y; Zhang Y; Cao Y; Bai LD
    Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(29):2030-5. PubMed ID: 21029638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.
    Lautenschlager M; Heinz A
    Expert Rev Neurother; 2008 Feb; 8(2):193-200. PubMed ID: 18271706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.
    Si TM; Zhang YL; Feng Y; Zhuo JM; Cai S; Zhang L
    Psychiatry Res; 2019 Apr; 274():301-305. PubMed ID: 30831454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paliperidone extended-release for the treatment of schizophrenia.
    Marino J; Caballero J
    Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.
    Canuso CM; Battisti WP
    Expert Opin Pharmacother; 2010 Oct; 11(15):2557-67. PubMed ID: 20854185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia.
    Na KS; Kim WH; Jung HY; Ryu SG; Min KJ; Park KC; Kim YS; Yoon JS; Ahn YM; Kim CE
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):295-300. PubMed ID: 22796278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
    Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
    Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower subjective quality of life and the development of social anxiety symptoms after the discharge of elderly patients with remitted schizophrenia: a 5-year longitudinal study.
    Kumazaki H; Kobayashi H; Niimura H; Kobayashi Y; Ito S; Nemoto T; Sakuma K; Kashima H; Mizuno M
    Compr Psychiatry; 2012 Oct; 53(7):946-51. PubMed ID: 22554765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
    J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
    Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
    J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.